跳至主要内容
临床试验/NCT03103321
NCT03103321已完成3 期

Testing Decision Aids to Improve Prostate Cancer Decisions for Minority Men

Alliance for Clinical Trials in Oncology56 个研究点 分布在 1 个国家目标入组 158 人开始时间: 2017年10月2日最近更新:
适应症
干预措施

试验速览

阶段
3 期
状态
已完成
入组人数
158
试验地点
56
主要终点
Knowledge Assessed by Prostate Cancer Treatment Questionnaire

研究概览

简要总结

This randomized phase III trial studies how well decision aids work in improving knowledge in patients with newly diagnosed prostate cancer. Decision aids may improve patients' knowledge of their condition and options for treatment, and may also help when talking with their doctor.

详细描述

PRIMARY OBJECTIVES:

I. To test the comparative effectiveness of decision aids (DA's) on patient knowledge.

SECONDARY OBJECTIVES:

I. To test the impact of in-visit DA's alone compared to usual care on quality of life outcomes and treatment utilization.

II. To test the impact of out-of-visit DA's alone compared to usual care on quality of life outcomes and treatment utilization.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Health Services Research
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Patients must have prostate biopsy within 4 months prior to registration showing newly diagnosed prostate cancer, stage T1-3N0M0; in addition, patients must have: Gleason score 6-10
  • Prostate-specific antigen (PSA) < 50 ng/mL
  • Patients who have had a history of non-cutaneous malignancy in the previous 5 years are not eligible; exception: patients with history of non-melanoma skin cancer are eligible
  • Scheduled prostate cancer consultation to be the first consultation after diagnosis (i.e. not a second-opinion or a consultation following previous discussions of treatment options)
  • Patients may not be concurrently enrolled to another clinical trial for the treatment of cancer; co-enrollment to biospecimen studies is allowed
  • Patients with impaired decision-making capacity (such as with a diagnosis of dementia or memory loss) are not eligible for this study
  • Patients must be able to read and comprehend English; non-English-speaking patients may participate so long as an interpreter (e.g., family member, clinic staff, etc.) is present for consent, for the decision aid administration, and gathering of baseline and follow-up measures

排除标准

  • 未提供

研究组 & 干预措施

Arm D (usual care)

Active Comparator

Patients undergo usual care.

干预措施: Quality-of-Life Assessment (Other)

Arm A ("Knowing your Options", "Prostate Choice")

Experimental

Patients receive decision aids "Knowing your Options" before and "Prostate Choice" during their consultation visit.

干预措施: Internet-Based Intervention (Other)

Arm A ("Knowing your Options", "Prostate Choice")

Experimental

Patients receive decision aids "Knowing your Options" before and "Prostate Choice" during their consultation visit.

干预措施: Quality-of-Life Assessment (Other)

Arm A ("Knowing your Options", "Prostate Choice")

Experimental

Patients receive decision aids "Knowing your Options" before and "Prostate Choice" during their consultation visit.

干预措施: Questionnaire Administration (Other)

Arm A ("Knowing your Options", "Prostate Choice")

Experimental

Patients receive decision aids "Knowing your Options" before and "Prostate Choice" during their consultation visit.

干预措施: Survey Administration (Other)

Arm A ("Knowing your Options", "Prostate Choice")

Experimental

Patients receive decision aids "Knowing your Options" before and "Prostate Choice" during their consultation visit.

干预措施: Laboratory Biomarker Analysis (Other)

Arm B ("Knowing your Options")

Experimental

Patients receive "Knowing your Options" decision aid before their consultation visit.

干预措施: Internet-Based Intervention (Other)

Arm B ("Knowing your Options")

Experimental

Patients receive "Knowing your Options" decision aid before their consultation visit.

干预措施: Quality-of-Life Assessment (Other)

Arm B ("Knowing your Options")

Experimental

Patients receive "Knowing your Options" decision aid before their consultation visit.

干预措施: Questionnaire Administration (Other)

Arm B ("Knowing your Options")

Experimental

Patients receive "Knowing your Options" decision aid before their consultation visit.

干预措施: Survey Administration (Other)

Arm B ("Knowing your Options")

Experimental

Patients receive "Knowing your Options" decision aid before their consultation visit.

干预措施: Laboratory Biomarker Analysis (Other)

Arm C ("Prostate Choice")

Experimental

Patients receive "Prostate Choice" decision aid during their consultation visit.

干预措施: Internet-Based Intervention (Other)

Arm C ("Prostate Choice")

Experimental

Patients receive "Prostate Choice" decision aid during their consultation visit.

干预措施: Quality-of-Life Assessment (Other)

Arm C ("Prostate Choice")

Experimental

Patients receive "Prostate Choice" decision aid during their consultation visit.

干预措施: Questionnaire Administration (Other)

Arm C ("Prostate Choice")

Experimental

Patients receive "Prostate Choice" decision aid during their consultation visit.

干预措施: Survey Administration (Other)

Arm C ("Prostate Choice")

Experimental

Patients receive "Prostate Choice" decision aid during their consultation visit.

干预措施: Laboratory Biomarker Analysis (Other)

Arm D (usual care)

Active Comparator

Patients undergo usual care.

干预措施: Best Practice (Other)

Arm D (usual care)

Active Comparator

Patients undergo usual care.

干预措施: Questionnaire Administration (Other)

Arm D (usual care)

Active Comparator

Patients undergo usual care.

干预措施: Survey Administration (Other)

Arm D (usual care)

Active Comparator

Patients undergo usual care.

干预措施: Laboratory Biomarker Analysis (Other)

结局指标

主要结局

Knowledge Assessed by Prostate Cancer Treatment Questionnaire

时间窗: 12 months

The primary outcome, knowledge, will be assessed by a standardized questionnaire (i.e., Prostate Cancer Treatment Questionnaire) administered once, immediately after the clinical consultation while the patient is still at the study site. The number correct from this 12-item measure will be reduced to a percentage of total number correct. With 100%(12 out of 12 item average) being the best possible outcome and 0%(0 out of 12 item average) the worst possible outcome

次要结局

  • Decisional Quality as Measured by Decisional Conflict Scale Decisional Regret(12 months)
  • Utilization as Determined by Chart Review(12 months)
  • Clinical Time Required(12 months)
  • Quality of Life Assessed by Questionnaire(12 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (56)

Loading locations...

相似试验